Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression

Objective: Overweight and obesity are endemic in developed countries, with a substantial negative impact on human health. Medications developed to treat obesity include agonists for the G-protein coupled receptors glucagon-like peptide-1 (GLP-1R; e.g. liraglutide), serotonin 2C (5-HT2CR; e.g, lorcas...

Descripció completa

Dades bibliogràfiques

Autors principals:	Stefan Wagner, Daniel I. Brierley, Alasdair Leeson-Payne, Wanqing Jiang, Raffaella Chianese, Brian Y.H. Lam, Georgina K.C. Dowsett, Claudia Cristiano, David Lyons, Frank Reimann, Fiona M. Gribble, Pablo B. Martinez de Morentin, Giles S.H. Yeo, Stefan Trapp, Lora K. Heisler
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2023-02-01
Col·lecció:	Molecular Metabolism
Matèries:	Lorcaserin Liraglutide Preproglucagon Nucleus tractus solitarii Brainstem Serotonin 2C receptor
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2212877822002344
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!